期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

白介素33与常见自身免疫性疾病 被引量：2

Interleukin-33 and common autoimmune disease
原文传递
导出
摘要 白介素1家族的细胞因子在许多炎性和传染性疾病的宿主防御和免疫调节中都起着重要的作用。白介素33(interleukin-33,IL-33)是白介素1家族的一个新的细胞因子,它可以作为一种分泌性细胞因子参与Th2细胞免疫应答的调节,并且具有前炎性因子的作用。IL-33在自身免疫性疾病中发挥着重要的作用,对其功能的研究,可能会为探索这些疾病的发病机制、寻找治疗靶点提供新的思路。 Members of the interleukin-1 family of cytokines play key roles in host defense and immune system regulation in inflammatory and infectious diseases.Interleukin-33（IL-33） is a new cytokine of interleukin-1 family,as a secreted cytokine,it can be involved in the regulation of Th2 immune response,and has the role of pro-inflammatory cytokines.IL-33 plays an important role in autoimmune disease.Exploration of the function of IL-33 might shed a light on defining the mechanism of these diseases and finding novel therapeutic targets for the treatment.
作者 李桂兴 高静 潘发明
机构地区 安徽医科大学公共卫生学院流行病与卫生统计学系
出处 《中华疾病控制杂志》 CAS 北大核心 2012年第7期618-620,共3页 Chinese Journal of Disease Control & Prevention
基金 国家自然科学基金(30771849 30972530) 安徽省自然科学基金(090413133)
关键词 白细胞介素类 细胞因子类 自身免疫疾病 Interleukins Cytokines Autoimmune diseases
分类号 R593.2 [医药卫生—内科学]
  • 相关文献

参考文献22

  • 1张临友,高源.设计树突状细胞疫苗诱发外周免疫耐受治疗自身免疫疾病[J].国外医学（免疫学分册）,2004,27(2):83-87. 被引量：1
  • 2李彦军.基因治疗在自身免疫疾病研究中的应用[J].国外医学（免疫学分册）,2003,26(5):251-254. 被引量：1
  • 3Sehmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1 - like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines [J]. Immunity, 2005,23 (5) :479-490.
  • 4Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigen-in- duced arthritis by activating mast cells [ J]. Proc Natl Aead Sei U S A, 2008,105(31 ) :10913-10918.
  • 5Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-l-like cyto- kine ligand for ST2 receptor, is a chromatin-assoeiated nuclear fac- tor in vivo [J]. Proe Natl Acad Sci U S A, 2007,104( 1 ) :282- 287.
  • 6Trajkovic V, Sweet MJ, Xu D. T1/ST2--an IL-I receptor-like modulator of immune responses [ J]. Cytokine Growth Factor Rev, 2004,15 (2-3) :87-95.
  • 7Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor ac- cessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33 [ J ]. Cyto- kine, 2008,42 ( 3 ) :358-364.
  • 8Chackerian AA, Oldham ER, Murphy EE, et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex [J]. J Immunol, 2007,179(4) :2551-2555.
  • 9Ali S, Huber M, Kollewe C, et al. IL-I receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells [J]. Proc Natl Acad Sci U S A, 2007,104 (47):18660- 18665.
  • 10Dinarello CA. An IL-1 family member requires caspase-1 pro- cessing and signals through the ST2 receptor [ J ]. Immunity, 2005,23 ( 5 ) :461-462.

二级参考文献79

  • 1陈伟,李向培,翟志敏,陶金辉,汪国生,张宏,钱龙.系统性红斑狼疮患者调节性T细胞及相关细胞因子的变化[J].疾病控制杂志,2007,11(1):33-36. 被引量：1
  • 2Pascual V,Allantaz F,Patel P,et al.How the sutdy of children with rheumatic diseases identified interferon-alpha and interliukin-1 as novel therapeutic targets[J].Immunol Rev,2008,223:39-59.
  • 3Aringer M,Smolen JS.Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus:a rationale for therapeutic intervention[J].Lupus,2004,13(5):344-347.
  • 4Carriere V,Roussel L,Ortega N,et al.IL-33,the IL-1-like cytokine ligand for ST2 receptor,is a chromatin-associated nuclear factor in vivo[J].Proc Natl Acad Sci USA,2007,104(1):282-287.
  • 5Palmer G,Talabot-Ayer D,Lamacchia C,et al.Inhibition of interleukin-33 signaling attenuates the severity of expreimental arthritis[J].Arthritis & Rheumatism,2009,60(3):738-749.
  • 6Gabay C,Mclnnes LB.The biological and clinical importance of the ‘new generation'cytokines in rheumatic diseases[J].Arthritis Research & Therapy,2009,11(3):230-243.
  • 7Hochberg MC.Updating the American College of R-heumatology revised criteria for the classification of systemic lupus erythematosus[letter].Arthritis Rheum,1997,40(9):1725.
  • 8Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria.The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials[J].Arthritis Rheum,2006,54(2):421-432.
  • 9Mohan C,Adams S,Stanik V,et al.Nucleosome:a major immunogen for pathogenic autoantibody-inducing T cells of lupus[J].J Exp Med,1993,177(5):1367-1381.
  • 10Houssiau FA,Lefebvre C,Vanden Berghe M,et al.Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity[J].Lupus,1995,4(5):393-395.

共引文献3

同被引文献11

引证文献2

二级引证文献4

中华疾病控制杂志
2012年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部